


## TM5441

<b>Cat. No.:</b>	HY-101761		
<b>CAS No.:</b>	1190221-43-2		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>17</sub> ClN <sub>2</sub> O <sub>6</sub>		
<b>Molecular Weight:</b>	428.82		
<b>Target:</b>	PAI-1; Apoptosis		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (233.20 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.3320 mL	11.6599 mL	23.3198 mL
		5 mM	0.4664 mL	2.3320 mL	4.6640 mL
10 mM		0.2332 mL	1.1660 mL	2.3320 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC <sub>50</sub> values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced cardiac hypertension and vascular senescence <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 13.9~51.1 μM (Tumor cell lines) <sup>[1]</sup>
<b>In Vitro</b>	TM5441 dose-dependently decreases HT1080, HCT116, Daoy, MDA-MB-231 and Jurkat cells with an IC <sub>50</sub> ranging between 13.9 and 51.1 μM <sup>[1]</sup> . TM5441 increases caspase 3/7 activity for both HT1080 and HCT116 cells in a dose dependant manner. TM5441 increases apoptosis in HT1080 and HCT116 cells <sup>[1]</sup> .

TM5441 induces mitochondrial depolarization<sup>[1]</sup>.  
In mouse proximal tubular epithelial cells, TM5441 effectively inhibits PAI-1-induced mRNA expression of fibrosis and inflammation markers and also reverses PAI-1-induced inhibition of plasmin activity<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Oral administration of TM5441 (20 mg/kg daily) to HT1080 and HCT116 xenotransplanted mice increases tumor cell apoptosis and has a significant disruptive effect on the tumor vasculature that is associated with a decrease in tumor growth and an increase in survival. The average peak plasma concentration is 11.4  $\mu$ M one hour after oral administration and undetectable levels 23 hours after administration<sup>[1]</sup>.  
TM5441 attenuates N $\omega$ -nitro-L-arginine methyl ester-induced cardiac hypertension and vascular senescence, prolongs lifespan in klotho null mice and elicits anti-tumorigenic and anti-angiogenic activities in cancer<sup>[3]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay <sup>[1]</sup>

HT1080, HCT116, Daoy, MDA-MB-231 and Jurkat cells are treated with 0-100  $\mu$ M TM5441 for 48 hours at 37°C. Cell viability is measured by MTT assay<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[2]</sup>

Mice: TM5275 at 50 mg/kg/day and TM5441 at 10 mg/kg/day were orally administered in control and diabetic mice for 16 weeks. Mice were monitored at least once a day. At the end, blood is collected for measurement of plasma glucose and creatinine, urine for protein measurement, and kidneys for immunohistochemical analysis<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Kidney Int. 2023 Jun 23;S0085-2538(23)00425-8.
- Sci Rep. 2023 Sep 27;13(1):16210.
- Eur J Pharm Sci. 2020 Feb 15;143:105195.
- Biol Pharm Bull. 2023 Oct 10;46(12):1753-1760.
- bioRxiv. 2023 Nov 26.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Placencio VR, et al. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS One. 2015 Jul 24;10(7):e0133786.

[2]. Jeong BY, et al. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model. PLoS One. 2016 Jun 3;11(6):e0157012.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA